Supplementary Figure 1 from Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

Kaplan-Meier estimates of overall survival</p

Supplementary Figure 2 from Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

Kaplan-Meier estimates of progression-free survival by baseline metabolic status</p

Supplementary Figure 3 from Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

Gene expression signatures by PIK3CA mutation status</p

Supplementary section from Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

Supplementary text</p

Figure S2 from Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

Recurrence-free survival and overall survival in the overall patient population</p

Supplemental Material Description from Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts

Supplemental material contains names of participating institutions for the Spanish MMJ-CAR-2014-01 cohort, details on local guidelines for positive family history, tables depicting the relationship between pathological response and family history, pathological response and ER/PR status and univariate analysis of predictors of RCB 0+1. Supplemental Table 1. Pathological response and Family history of breast and ovarian cancer Supplemental Table 2. Pathological response by ER/PR Supplement Table 3. Predictors of RCB 0+1 on univariate analysis</p

Figure S1 from Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

Pathological response to carboplatin plus docetaxel by germline BRCA status</p

Supplementary Methods and Results from Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

Further description of patient population and exploratory analysis.</p

Figure S3 from Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

Recurrence-free survival and overall survival by adjuvant chemotherapy use in RCB II/III patients</p